医学
药品
药理学
产品特性概述
药物输送
不利影响
离体
更年期
重症监护医学
泌尿生殖系统
指南
随机对照试验
临床试验
妇科
内科学
药代动力学
体内
药物治疗
给药途径
外科
剂型
治疗效果
作者
Ahmed Abdelgader,Mershen Govender,Pradeep Kumar,Yahya Essop Choonara
标识
DOI:10.1016/j.ijpharm.2025.126195
摘要
• The novel dual-compartment device delivers hormones for targeted GSM therapy. • The design addresses dosing concerns, release control, and user acceptability. • A factorial design optimized device integrity and drug release. • A 3D bio-printed uterine-vaginal model provided realistic in vitro assessments. • The device releases hormones over 4 weeks, providing over 70 % cell viability. The Genitourinary Syndrome of Menopause (GSM) affects millions of women worldwide, with current treatment regimens associated with frequent dosing, inconsistent release profiles, and systemic adverse effects, leading to a decreased patient acceptability. Patient acceptability is pivotal in ensuring adherence and therapeutic outcomes and is defined by the European Medicines Agency as “an overall ability of the patient and caregiver to use a medicinal product as intended” with the International Conference on Harmonization Pharmaceutical Development Guideline (Q8 (R2)) further stating “in all cases, the product should be designed to meet patients’ needs and the intended product performance”. Accordingly, this study focuses on the development of a multi-unit, polymer-based, intravaginal-intrauterine platform (MUPP) for targeted and controlled hormone delivery with the aim of GSM treatment. The platform comprises of a doughnut-shaped intravaginal device (DVDS) releasing estradiol hemihydrate (E2) and an intrauterine cylindrical unit (NLPM) delivering norethindrone acetate (NETA). An experimental design was implemented to optimize DVDS formulation. The optimized device was characterized in vitro , assembled with NLPM, and evaluated for their drug release, ex vivo permeation, and cytocompatibility, using 3 T3/NIH cells and a 3D-engineered uterine-vaginal cellular model (EUVM). Results showed that the optimal DVDS and NLPM displayed cumulative releases of 5.84 ± 0.24 % (E2) 38.00 ± 1.60 % (NETA) after 4 weeks, with maximum drug flux values (peak permeation rates) of 0.18 ± 0.05 mg⋅cm −2 ⋅h −1 and 0.01 ± 0.03 mg⋅cm −2 ⋅h −1 , respectively. Moreover, cytocompatibility analyses showed an average cell viability exceeding the ISO 10993–5 minimum threshold of 70 % after 3 days, rising to above 80 % by Day 7 in both 2D and 3D models, thereby confirming the non-cytotoxic nature of the platform. In conclusion, the MUPP presents a promising and patient-friendly approach to addressing the current challenges of GSM therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI